EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
暂无分享,去创建一个
Y. Ohe | K. Tsuta | T. Tamura | Seiichiro Yamamoto | T. Takano | H. Kunitoh | K. Furuta | N. Yamamoto | H. Nokihara | I. Sekine | T. Fukui